Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Down 42.9% in December

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 419,600 shares, a decrease of 42.9% from the November 30th total of 735,400 shares. Based on an average daily trading volume, of 702,800 shares, the days-to-cover ratio is currently 0.6 days.

Wall Street Analyst Weigh In

Separately, Leerink Partners lowered their price target on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th.

Institutional Trading of Vincerx Pharma

An institutional investor recently raised its position in Vincerx Pharma stock. Marshall Wace LLP raised its stake in shares of Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 328,533 shares of the company’s stock after purchasing an additional 256,967 shares during the period. Marshall Wace LLP owned 1.11% of Vincerx Pharma worth $266,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 44.02% of the company’s stock.

Vincerx Pharma Stock Performance

Shares of Vincerx Pharma stock traded up $0.01 during trading hours on Friday, hitting $0.19. The company’s stock had a trading volume of 17,339,961 shares, compared to its average volume of 746,792. The company has a market cap of $6.53 million, a PE ratio of -0.19 and a beta of 1.48. The business has a 50 day moving average price of $0.28 and a two-hundred day moving average price of $0.52. Vincerx Pharma has a 12-month low of $0.18 and a 12-month high of $9.37.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.